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Abstract
Background: Procalcitonin (PCT), a precursor protein of the hormone calcitonin, is a sensitive inflammatory marker
in human medicine, which is primarily used for diagnosis of bacterial sepsis, but is also useful in diagnosis of
exacerbation of asthma and COPD. In this study, PCT was evaluated as a potential biomarker for different chronic
pneumopathies in the horse using an equine specific ELISA in comparison to established clinical markers and
different interleukins.
Sixty-four horses were classified as free of respiratory disease, recurrent airway obstruction (RAO), inflammatory
airway disease (IAD) or chronic interstitial pneumopathy (CIP) using a scoring system. PCT concentrations were
measured in plasma (n = 17) and in the cell-free supernatant of bronchoalveolar lavage (n = 64). PCT concentrations
were correlated to interleukins IL-1ß and IL-6 in BALF, clinical findings and BALF cytology.
Results: The median PCT concentrations in plasma were increased in respiratory disease (174.46 ng/ml, n = 7)
compared to controls (13.94 ng/ml, n = 10, P = 0.05) and correlated to PCT in BALF supernatant (rs = 0.48). Compared to
controls (5.49 ng/ml, n = 15), median PCT concentrations in BALF supernatant correlated to the overall clinical score
(rs = 0.32, P = 0.007) and were significantly increased in RAO (13.40 ng/ml, n = 21) and IAD (16.89 ng/ml, n = 16), while
no differences were found for CIP (12.02 ng/ml, n = 12). No significant increases were found for IL-1 and IL-6 between
controls and respiratory disease in general as well as different disease groups.
Conclusions: Although some correlations were found between PCT in plasma, BALF supernatant and clinical scores,
PCT in BALF does not seem to be a superior marker compared to established clinical markers. PCT in plasma seems to
be more promising and a greater number of samples should be evaluated in further studies.
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Background
Since the 1970s, hypocalcemia and its correlation to sepsis
have been in the focus of research [1]. Procalcitonin
(PCT) is a precursor protein of the hormone calcitonin,
which regulates the calcium homeostasis by inhibition of
osteoclastic activity. In health, preprocalcitonin (prePCT)
is exclusively produced in the thyroid c-cells. Low concen-
trations of <0.1 ng/ml are found in human serum [2].
During sepsis, PCT is found in high concentrations in
blood and almost all tissues [3], but PCT is not only a pre-
cursor of calcitonin leading to hypocalcemia. It seems to
have another pathophysiologic role as an inflammatory
mediator and is found in almost all inflammatory processes
independent from hypocalcemia. Its synthesis can be trig-
gered by TNF-α and several interleukins [4, 5]. Despite
lower PCT concentrations in plasma compared to endotox-
emia and sepsis, differentiation between different forms of
pneumonia is possible [6–8] and chronic respiratory
diseases like asthma or COPD (chronic obstructive
pulmonary disease) are also characterized by increases in
PCT concentrations. As acute exacerbation of asthma is
often caused by bacterial infections of the lower airways,
PCT can be used for the decision pro or contra the initi-
ation and duration of antibiotic therapy [9] and can help in
the interpretation of indifferent thoracic radiographs [10].
Similar results have been found for COPD, where PCT
measurement can support the decision for individual
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therapy involving antibiotics or glucocorticoids and is con-
sidered to be helpful in long-term management [11, 12].
Equine RAO (recurrent airway obstruction) is known
for parallels to human asthma (respiratory hypersensitiv-
ity, good response to bronchodilators and glucocorticoids)
as well as COPD (airway neutrophilia, epithelial metapla-
sia and hypersecretion into the lower airways), resembling
what is called “wheezy bronchitis” in men [13]. During
disease exacerbation, increased inflammatory markers
may be found in plasma as described for haptoglobin and
serumamyloid A [14], but local neutrophila in bronchoal-
veolar lavage fluid (BALF) is considered the most reliable
feature [15]. Inflammatory airway disease (IAD), a possible
precursor of RAO [16], shows a lower grade of inflamma-
tion including airway neutrophilia and/or increases in
mast cell and eosinophil counts [17], while interstitial
pneumopathies are characterized by increases in macro-
phage percentages in BALF cytology [18, 19]. As systemic
markers were only increased in RAO exacerbation, meas-
urement of biomarkers may be more rewarding out of
BALF in chronic respiratory disease. High disease preva-
lence and economic impact have been described for
equine chronic respiratory disease, therefore new
biomarkers may help to differentiate these pneumopathies
and to identify cases of subclinical disease. A species spe-
cific ELISA for equine PCT (ePCT) was established [20],
which allows quantitative measurements instead of gene
expression with a high specificity and sensitivity. High
ePCT concentrations were found in plasma of endotoxe-
mic horses suffering from colic [21, 22].
In this study, we aimed to compare ePCT concentra-
tions in BALF with clinicals findings, BALF cytology and
other biomarkers, namely interleukins 1ß and 6, which
have been shown to stimulate hyperprocalcitonemia in
other species [4, 23]. Additionally, ePCT concentrations
were measured in plasma. We hypothesized that ePCT
correlates with clinical scores, BALF cytology and inter-
leukins in RAO, IAD and CIP and may be a superior
marker in cases of low-grade inflammation.
Methods
Preparticipation examination
A total of 71 horses were examined, of which 15 had no
clinical signs or history of respiratory disease and 56
were presented to the clinic with a history of chronic
lower airway disease.
The pre-participation examination included anamnesis
documentation, clinical examination, exercise test, blood
gas analysis, bronchoscopy, BALF cytology and thoracic
radiography. Using a modified clinical score system [24,
25], endoscopy score results, parameters of gas
exchange, BALF cytology and thoracic radiography
results, horses were classified as free of respiratory
disease (controls, group I), Recurrent airway obstruction
in exacerbation (RAO, group II), Inflammatory airway
disease (IAD, group III), chronic interstitial pneumopa-
thy (CIP, group IV) or were excluded from the study, if
they could not be assigned to these groups (n = 7). In
detail, groups were defined as follows:
 Group I: No history of respiratory disease, clinical
score < 2, no tracheal secretions, low cellular density
and neutrophils ≤ 8% in BALF, AaDO2 ≤ 8 mmHg,
exclusion of acute signs of infection (leukocytosis,
fever, depression).
 Group II: History of recurrent cough or dyspnea,
clinical score > 6, high amount or viscosity of
tracheal secretions, high cellular density and
neutrophils ≥ 25% in BALF, AaDO2 > 8 mmHg,
exclusion of acute signs of infection (leukocytosis,
fever, depression) according to Robinson [15].
 Group III: History of cough or exercise insufficiency,
clinical score 2–6, low to moderate amount or
viscosity of tracheal secretions, increased cellular
density and neutrophils ≥ 8% or mast cells ≥ 2% or
eosinophils ≥ 0.1% in BALF, exclusion of acute signs
of infection (leukocytosis, fever, depression)
according to Couëtil et al. [17].
 Group IV: History of exercise insufficiency, clinical
score 2–6, low to moderate amount or viscosity of
tracheal secretions, increased cellular density and
ratio of macrophages:neutrophils ≥ 2.5:1 in BALF,
increased interstitial opacity of thoracic radiographs,
exclusion of acute signs of infection (leukocytosis,
fever, depression) according to Dieckmann et al.
[18].
BALF collection and processing
During endoscopy, 20 ml of 2% lidocaine (Bela-Pharm
GmbH, Vechta, Germany) were infused around the
tracheal bifurcation. The catheter (Silicone Bronchoalve-
olar Lavage Catheter 300 cm, Smiths Medical ASD, Inc,
USA) was wedged into the bronchus by mean of an air
balloon. Five hundred milliliters of pre-warmed
phosphate buffered saline (Phosphate buffered saline,
Lonza, Verviers, Belgium) were infused as recommended
by the International Workshop on Equine Chronic
Airway disease [15] and immediately aspirated.
BALF was divided into 2 portions for cytological and
biochemical examination. After centrifugation at
1500 rpm for 10 min at 4 °C the cell-free supernatant
was stored at −80 °C until assayed. Cytology was per-
formed using Wright-Giemsa staining and counting 500
cells at 500× magnification.
ELISA for quantification of ePCT in plasma and BALF
As the ELISA for equine PCT was only validated for
plasma, it was adapted to BALF according to the
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guidelines of the American Food and Drug Administra-
tion for Validation of bioanalytic methods (2013) by
partial validation which was done here by reanalyzing
intra-assay (IaA) and inter-assay (IeA) coefficients of
variation (CV) and recovery in BALF matrix (Table 1).
Measurements of PCT in plasma
In 17 horses (10 controls, 7 horses with respiratory
disease), PCT was measured in plasma using a specific
ELISA for equine PCT [20]. As this was not part of the
original study, we did not have plasma samples available
from all horses.
Measurements of PCT in BALF
In 64 horses, PCT was measured in undiluted BALF
supernatant samples using a specific ELISA for equine
PCT [20] after adaption to this substrate.
Measurements of interleukins
In 64 horses, interleukins was measured in undiluted BALF
samples using commercially available specific ELISAs for
equine IL-1ß and 6 (ELISA Kit for Interleukin 1 Beta
(IL1b) and ELISA Kit for Interleukin 6 (IL6), Uscn Life
Science Inc, USA) according to the manufacturer’s manual.
Statistical analysis
Data were statistically analyzed using SPSS (SPSS Statis-
tics, Version 17.0 released 2008, SPSS Inc., USA) and
expressed as median (min-max). The data were tested
for normal distribution using the Kolmogoronov-
Smirnov and Shapiro Wilks Test. The level of signifi-
cance was set at P 0.05.
Kruskal Wallis H test was used to compare between
controls and different disease groups followed by Post-
Hoc testing using Mann-Whitney U Test for 2-group
comparison to determine intergroup differences.
Spearman rank correlation coefficients were calculated
between clinical parameters, cytologic data, PCT and
interleukin concentrations. Correlations were classified
as irrelevant (rs = 0–0.25), weak (rs = 0.25–0.5), moder-
ate (rs = 0.5–0.75) and strong (rs > 0.75).
Results
Clinical scoring
According to the results of clinical scoring and BALF
cytology, the 71 horses (42 geldings, 29 mares, age 12.5 ±
5.31 years, BDW 470.8 ± 91.3 kg) presented for participa-
tion in this study were classified as follows: 15 horses were
classified as free of respiratory disease (group I, controls),
21 as RAO (group II), 16 as IAD (group III), 12 as chronic
interstitial pneumopathy (group IV), 4 horses suffered
from acute respiratory infections and 3 could not be
clearly assigned to groups I-IV. Therefore, the later 7 were
excluded, leaving 64 horses for statistical analysis.
Hematology and ionized calcium
In all 64 horses, controls and horses affected by respira-
tory disease, hematology was unremarkable. Leucocytes
(8.1 ± 2.2 * 103/μl), hematocrit (35 ± 5.1%), total protein
(6.7 ± 0.5 g/dl) and ionized calcium (1.64 ± 0.10 mmol/l)
were within normal limits. There was no difference
between in ionized calcium between controls (1.58 ±
0.11 mmol/l) and horses affected by respiratory disease
in groups II-IV (1.65 ± 0.09 mmol/l).
Measurements of PCT in plasma
In 17 horses (10 controls, 7 affected by respiratory disease),
PCT was measured in plasma using a specific ELISA for
equine PCT [20]. Overall PCTconcentrations in respiratory
disease (174.46 ng/ml, n = 7) were higher than in group I
(controls, 13.94 ng/ml, n = 10). The median concentrations
in group II (RAO) was even 482.23 ng/ml (n = 4).
Adaption of PCT ELISA to BALF
According to the guidelines of the American Food and
Drug Administration for Validation of Bioanalytic Methods
Table 1 Concentrations spiked (Concspik) and found (Concfound), intra-assay (IaA) and inter-assay (IeA) coefficients of variation (CV)
and recovery-values for equine PCT ELISA in BALF
Sample Concspik[ng/ml] Concfound[ng/ml] IaA-CV (%) IeA-CV (%) Recovery (%)
1 10 15.6 ± 4.7 30.4 10.9 156
2 25 24.9 ± 0.7 2.7 8.4 99.2
3 50 43.2 ± 2 4.7 3.1 86.2
4 100 102.6 ± 13.9 13.6 11.4 102.5
5 250 377 ± 22.3 5.9 7 150.8
6 500 658.5 ± 248 37.7 16.1 131.6
7 1.000 * * * *
8 5.000 * * * *
9 10.000 * * * *
The working range is marked in bold
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(2013) the variation coefficients in medical ELISAs need to
be below 15%, therefore the working range for equine
BALF was defined as 25–250 ng/ml, as shown in Table 1.
Measurements of PCT in BALF
In 64 horses, PCT was measured in undiluted BALF
supernatant using a specific ELISA for equine PCT [20]
after adaption to this substrate. The median concentra-
tion in group I (controls, 5.49 ng/ml) as well as in
groups II-IV was below the defined working range of the
ELISA (25–250 ng/ml). PCT was significantly increased
in groups II (RAO, median13.40 ng/ml) and III (IAD,
median 16.89 ng/ml), while no differences were found
for group IV (CIP, median 12.02 ng/ml), Table 2 and
Fig. 1. Significant inter-group differences were found
between groups I (controls) and II (RAO, P = 0.033) as
well as groups I and III (IAD, P = 0.006).
Correlation of PCT to clinical parameters
A weak correlation was found between PCT concentra-
tions in plasma and BALF supernatant (rs = 0.48, P =
0.060). The highest correlation was found between PCT in
plasma and the respiratory rate (rs = 0.53, P = 0.025).
Negative correlations were found between PCT in plasma
and the arterial PaO2 (rs = −0.60, P = 0.009). A weak cor-
relation was found between PCT concentration in BALF
and airway obstruction (rs = 0.42, P = 0.010) as well as
overall clinical score (rs = 0.32, P = 0.007). Neither PCT in
plasma nor in BALF supernatant correlated to the
percentage of neutrophils in BALF cytology, but PCT in
plasma with the eosinophils (rs = −0.49, P = 0.039).
Measurements of interleukins in BALF
In 64 horses, interleukin concentrations were measured
in undiluted BALF samples using a specific ELISA for
equine IL-1ß and IL-6. No significant increases were
found for IL-1ß or IL-6 between group I (controls) and
groups II-IV in general (P = 0.122) or between controls
and single disease groups (P = 0.365). Results are shown
in detail in Table 2.
Discussion
In the late 1990s, it has been shown that procalcito-
nin is a sensitive marker for systemic inflammatory
processes caused by bacterial infection, but not of
other pathogenesis [26–28]. While exacerbations of
asthma and COPD in men are often triggered by viral
and bacterial infection of the lower airways [29, 30],
Table 2 Median values of PCT and interleukin concentrations in
BALF supernatant over different disease groups, significance
(P < 0.05) is indicated by*
Diagnosis PCT [ng/ml] IL-1β [pg/ml] IL-6[pg/ml]
























Fig. 1 PCT concentrations (0–250 ng/ml) in BALF over different disease groups (n = 59). Five samples had PCT values > 250 ng/ml and were
excluded from this graph, but not from statistical analysis. ° shows outliers 1.5–3 times out of the interquartile range, * shows extreme outliers
> 3 times out of the interquartile range
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this is not a common feature in RAO [31]. In IAD,
however, microbiologic examinations of tracheal aspi-
rates are often positive despite no evidence of sys-
temic infection [32]. Interstitial pneumonia may also
be the consequence of bacterial infection, but in the
phase of chronic interstitial disease it is usually im-
possible to find evidence of bacterial disease [19].
Equine PCT was characterized in the early 2000s [33].
Hypocalcemia in case of acute systemic disease was also
found in horse [34]. Low plasma levels of ionized calcium
were found in severe colic, gastrointestinal inflammation
and induced endotoxemia [35, 36]. Studies in horses suf-
fering from acute or chronic respiratory disease have not
been published so far. In our study, concentrations of ion-
ized calcium were within normal limits, both in healthy
controls and in horses affected by chronic pneumopathies.
Of course, chronic respiratory disease is not commonly
associated with endotoxemia, but ePCT may have a pro-
inflammatory function independent from its role in
calcium metabolism, possibly playing a role in chronic
respiratory disease. It was shown in other species that
anti-PCT antibodies increase the chance of survival after
induced endotoxemia [37–39].
For the quantification of ePCT in plasma and BALF a
validated sandwich ELISA using human anti-PCT
Antibodies and equine recombinant PCT (erPCT) as
standard was used [20]. Rieger et al. [20] showed that
the assay has a working range of 25–1000 ng/mL. The
authors stated parallelism up to a concentration of
10.000 ng/mL. Higher concentrations of ePCT led to
irregularities in quantification regarding different dilu-
tions. However, the authors showed acceptable values
for IaCv and Recovery resulting in a working range of
25–1000 ng/mL. Changing the matrix for validated
immunoassays can be done by partial validation which
was done here by reanalyzing IaCV/IeCV and recovery
in BALF matrix. Although the working range was
defined to be 25–250 ng/mL, lower concentrations can
be reported with this assay, but results must be regarded
with caution, as variability at 10 ng/mL (which was
approximately the BALF PCT concentration within this
study) is higher (30%). For future studies in BALF, the
method has to be improved e.g., by immunoaffinity
enrichment of ePCT before analyzing the samples in the
assay or the development of a more sensitive method,
for example electrochemiluminescence (ECl).
In human medicine, PCT concentrations are routinely
measured systemically from blood samples. A good
correlation has been found between PCT in serum and
BALF [40, 41]. Studies focusing on PCT in BALF
samples only, however, have led to disappointing results.
In some cases, very low concentrations were found in
the alveolar space making it impossible to use PCT in
the differentiation of pulmonary disease [40–44]. Low
sensitivity of methods of detection and the dilution ef-
fect of BALF may have been the reasons for this [40, 43].
In equine medicine, bronchoalveolar lavage is an easy to
perform and safe procedure to characterize airway in-
flammation and is recommended for the diagnosis of
common respiratory disease like RAO or IAD [15, 17].
Much higher ePCT concentrations were found in serum
of horses compared to men [20]. Therefore, it seemed
logical that alveolar concentrations might also be higher
in this species. Several biomarkers have been evaluated
in equine BALF, as it has been shown that chronic
respiratory disease does not always have a systemic com-
ponent and inflammatory processes may be localized to
the lung in case of minor disease like RAO in remission
[14]. As PCT in plasma is only increased in case of
systemic inflammation [45], we suspected that increases
in ePCT would be most obvious in the alveolar space,
but the results of our study show that it might be better
to measure ePCT concentrations in plasma. This might
be an advantage, as blood samples are much easier to
obtain than BALF, but should be confirmed in a higher
number of samples, as correlations based on different
numbers of samples have to be interpreted with caution.
ePCT in BALF allowed differentiating between controls
and chronic respiratory disease, while no differentiation
was possible between different disease groups. The highest
concentrations were found in RAO in exacerbation and
IAD, but inter-group-differences were insignificant. Again,
a higher number of samples may allow to establish reason-
able cut-off values for different types of disease.
A week positive correlation was found between PCT and
clinical score. In human asthma, a correlation between
PCT and the severity of disease has also been described [9].
Pro-inflammatory cytokines including IL-1ß and IL-6 are
involved in stimulation of PCT synthesis [4, 46]. As these
mediators also play a role in acute and chronic pulmonary
disease, we evaluated their concentration and correlation to
PCT in equine BALF. Nevertheless, no correlation was
found between PCT and these interleukins in our study.
Therefore, our results do not support their role in trigger-
ing PCT synthesis in the alveolar space.
For IL-1ß, no significant differences were found
between healthy controls and horses affected by chronic
respiratory disease in general and single disease groups,
while in former studies increased transcription and pro-
tein concentrations have been found in severe RAO
[47–50]. Similar results have been found for IAD [51,
52] and human asthma and COPD [53, 54]. In our study,
the highest concentrations were found in CIP, where IL-
1ß is known to stimulate the fibronectin and collagen
synthesis. Therefore, it is a direct mediator of pulmonary
fibrosis formation [54]. IL-1ß is produced by activated
macrophages, which are the dominant cell type in BALF
cytology in CIP.
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For IL-6, no significant differences were found between
healthy controls and horses affected by chronic respiratory
disease either. The highest median concentration was
found in group II (RAO in exacerbation). Former studies
have led to contrasting results. While some authors found
no significant increases in IL-6 were found in RAO
exacerbation [50, 55, 56], others describe increases about
three days after natural challenge [48, 52].
A weak point of this study was group definition, as sam-
ples were obtained from clinic patients. Therefore disease
status was not as uniform as in experimental studies,
where samples were obtained after defined disease induc-
tion. On the other hand, biomarkers are used in a clinical
setting, therefore it seems logical to evaluate their useful-
ness in the same situation. Although IAD and RAO in
remission were planned as two distinct groups, it was not
possible to differentiate clearly between these two. Anam-
nestic information of recurrent respiratory distress was
often unreliable and the majority of owners did not agree
to a natural challenge test. Descriptions of equine CIP are
rare in the literature and an international consensus state-
ment is missing, so definition of this group was based on a
quite old clinical case series including only 12 horses [18].
Thoracic radiography showing interstitial patterns is not
very specific for CIP and may also be found in RAO and
IAD [57, 58]. Again, the majority of owners did not agree
to lung biopsies. We tried to face these problems by calcu-
lating correlations between PCT and interleukins with
clinical and cytologic parameters over all 64 horses inde-
pendent of diagnosis.
Conclusions
In conclusion, correlations between PCT concentrations
in plasma and BALF supernatant were found and also
with clinical data, but PCT in BALF does not seem to be
a superior marker compared to established clinical
markers, in particular in cases of low-grade inflamma-
tion. Following the definition by Couëtil [17], a lower
grade of inflammation can be assumed in IAD compared
to RAO, but PCT was also not able to differentiate
between these two. There were significant differences
between controls and respiratory disease in general, but
differentiation between different forms of chronic pneu-
mopathies was not possible. PCT in plasma seems to be
a more promising marker, but its usefulness should be
evaluated in a higher number of cases.
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